{"nctId":"NCT00482729","briefTitle":"MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED)","startDateStruct":{"date":"2007-06-19","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":1246,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: sitagliptin phosphate (+) metformin hydrochloride"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: metformin"]}],"interventions":[{"name":"sitagliptin phosphate (+) metformin hydrochloride","otherNames":["MK0431A","Janumetâ„¢"]},{"name":"metformin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient has type 2 diabetes mellitus\n* Patient is greater than or equal to 18 and less than or equal to 78 years of age on the day of signing the consent\n* Patient has Hb1Ac greater than or equal to 7.5% and is appropriate for oral therapy\n* Patient has not been on any antihyperglycemic agent (AHA) in the last 4 months\n* Patient is a male, or a female who is unlikely to conceive\n\nExclusion Criteria:\n\n* Patient has type 1 diabetes mellitus or history of ketoacidosis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"78 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1c (A1C) at Week 18","description":"A1C is measured as percent. Thus, this change from baseline reflects the Week 18 A1C percent minus the Week 0 A1C percent.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.37","spread":null},{"groupId":"OG001","value":"-1.76","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With A1C < 7.0% at Week 18","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"275","spread":null},{"groupId":"OG001","value":"193","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"284","spread":null},{"groupId":"OG001","value":"371","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18","description":"FPG is measured as mg/dL. Thus, this change from baseline reflects the Week 18 FPG mg/dL minus the Week 0 FPG mg/dL.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-69.4","spread":null},{"groupId":"OG001","value":"-53.7","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in A1C at Week 44","description":"A1C is measured as percent. Thus, this change from baseline reflects the Week 44 A1C percent minus the Week 0 A1C percent.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.25","spread":null},{"groupId":"OG001","value":"-1.77","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients With A1C < 7.0% at Week 44","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"258","spread":null},{"groupId":"OG001","value":"173","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"302","spread":null},{"groupId":"OG001","value":"396","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":28,"n":625},"commonTop":["Any Gastrointestinal Disorders","Diarrhoea","Any Infections and infestations","Nausea","Upper respiratory tract infection"]}}}